Company analysis

Company Analysis: Otsuka

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook over 2019–29.

January 29, 2020

Company Analysis: Takeda

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.

January 29, 2021

Big Pharma Licensing Trends, 2011–15

$5,000.00

Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.

October 14, 2016

CMOs in China and India: Still the Places to be?

$5,000.00

Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.

November 3, 2016

2016 M&A Analysis

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how

they may influence the market and future deal-making.

September 7, 2016

Big Pharma Outlook 2025

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

December 20, 2016

Social Media in Pharma

While social media is still relatively new, it has been heralded as one of the most significant changes in the way that people communicate with one another. Despite this, the pharmaceutical industry has been slow to become involved with social media, fearing compliance and regulatory breaches and preferring to stay with the more traditional routes of communication, such as representative visits and emails. However, the growing popularity of social media, combined with a number of positive examples from both within and outside the pharmaceutical industry, has led to an increasing number of pharmaceutical companies looking to grow their social media presence and build on the unique opportunities these platforms offer.

January 27, 2017

Mid Pharma Licensing and M&A Trends, 2011–16

This analysis covers trends in alliance and mergers and acquisitions (M&A) agreements by Datamonitor Healthcare’s Mid Pharma peer set from 1 January 2011 through to 30 September 2016. Only deals involving drug discovery, development, or commercialization were considered for this analysis. All data were derived from Informa’s Strategic Transactions and Medtrack databases.

February 16, 2017

Big Pharma Licensing Trends, 2012–16

Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.

March 8, 2017

Immuno-Oncology Deal Trends, 2012–16

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.

April 19, 2017

Big Pharma Outlook 2026

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

June 29, 2017

Regenerative Medicine Landscape

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.

July 21, 2017

Pharma-Payer Partnerships in Emerging Markets

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.

July 26, 2017

Company Analysis: Shionogi

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.

January 29, 2021

Shire Company Analysis

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

August 30, 2018

Company Analysis: Johnson & Johnson

PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Incyte

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.

JP Morgan Healthcare Conference Preview

PharmaVitae previews companies presenting at the JP Morgan Healthcare Conference to be held in San Francisco over 8–11 January 2018.

January 10, 2018

JP Morgan Healthcare Conference Review

The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.

January 18, 2018

Company Analysis: BioMarin

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook over 2019–29.

Acorda Company Analysis

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.

February 9, 2018

Big Pharma Diversification Strategies

Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.

March 4, 2018

M&A Outlook 2018

PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.

April 24, 2018

Japan Pharma Outlook 2027

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.

July 2, 2018

M&A Analysis 2018

PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.

April 24, 2018

Under the Radar Takeover Targets

Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.

July 20, 2018

Company Analysis: Vertex

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

This decade has seen the emergence of therapies harnessing the immune system to treat cancer.

October 1, 2018

Company Analysis: GlaxoSmithKline

PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.